Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.
Also called NCT05376969
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 159 participants
- Registry
-
NCT05376969
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05376969. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-25 (actual); primary completion 2022-05-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
- Acronym
- ENHANCE-MEXT
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- DWP16001
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct05376969- Content hash
4c67e3987c36153a9b30a697c1e1f20cdd424ebf712b520a0df95bb119bc9613